Lecture 2 - Surrogate Endpoints in Oncology - Reading and Interpreting Cancer Trials

[@marchhair01]

So glad I found Dr Prasad. I'm an Oncology Nurse Educator and love love his perspective. I'm asking for 'Malignant' from Santa this year!

[@JCResDoc94]

*2:50** i think that is an MR: the room is too clean, and that doughnut too big.* you cant see coolant tube above it, and no coils or ports about. no wedges or straps: uncommon. but ports can be hidden. & she could be an actor. jewlery off - not required for either, but pts will more oft for MR. hard to know for sure - but unless it is the first CT: dam. that is a big gantry. WAIT! thats a coil under the pt's head!. . . oh, let it be debated in the comments. half a decade in MR, & when i needed those skills for a yt comment section, they abandoned me. _eventually_ some one come past w that exact machine in thr shop. or be this ladies talent agent. Gr8 lect.

[@kasongta]

I love this❤❤❤❤

[@KenNeumeister]

quality of life metric should include the quality of life of the loved ones and other care takers who have the burden of assisting the patient through the hard parts. Another relevant metric may be the burden on the healthcare system caused by treating or managing the side-effects and conditions caused by the treatment itself: this has an impact on diverting medical attention away from other patients who may otherwise have benefited from more attention.

[@JimHokanson]

Very interesting. I'd be interested in seeing some analysis comparing the individual components of PFS and OS. Does PFS with more death and new lesions correlate better with OS than PFS based on lesion size only?

[@andresmenacho274]

Thanks

[@jzam5426]

I came across your video and I'm really glad I stuck around to watch the whole thing. I loved the PFS description and the surrogate evidence discussion!!! I've always wanted to learn what determines wether a sponsor has to show benefit evidence on post-marketing follow up after they had initial approval using a surrogate. For example, if a sponsor utilized PFS in an RCT in Oncology, is it a 100% required that they will need to show evidence of benefit post-marketing? What happens if the see no benefit after it has been required (e.g. at 2, 5 or 10 years of follow-up), does the sponsor retires the drug from the market and relinquishes all gains post approval (I'm assuming not)? -- Where can I can get more information about this, can you point in the right direction?? Thank you!!!